

## Univ.-Prof. Dr. Martin Schindl – wichtige wissenschaftliche Publikationen

Aktualisiert 15. Jun. 2021

### Originalarbeiten

1. Bastati N, Kristic A, Poetter-Lang S, Messner A, Herold A, Hodge JC, **Schindl M**, Ba-Ssalamah A.  
Imaging of inflammatory disease of the pancreas.  
Br J Radiol. 2021 Jun 11:20201214. doi: 10.1259/bjr.20201214.
2. Kloesch B, Ionasz V, Paliwal S, Hruschka N, Martinez de Villarreal J, Öllinger R, Mueller S, Dienes HP, **Schindl M**, Gruber ES, Stift J, Herndler-Brandstetter D, Lomberk GA, Seidler B, Saur D, Rad R, Urrutia RA, Real FX, Martinelli P.  
A GATA6-centred gene regulatory network involving HNFs and  $\Delta Np63$  controls plasticity and immune escape in pancreatic cancer.  
Gut. 2021 Apr 12:gutjnl-2020-321397. doi: 10.1136/gutjnl-2020-321397.
3. Schwarz C, Fitschek F, Primavesi F, Stättner S, Margonis GA, Weiss MA, Stavrou GA, Oldhafer KJ, Kornprat P, Wundsam H, Fischer I, Längle F, Függer R, Hauer A, Klug R, Kieler M, Prager G, **Schindl M**, Stremitzer S, Bodingbauer M, Sahora K, Kaczirek K.  
Metachronous hepatic resection for liver only pancreatic metastases  
Surg Oncol. 2020 Dec;35:169-173. doi: 10.1016/j.suronc.2020.08.005.
4. Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, **Schindl M**.  
The prognostic index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection.  
Ann Surg Oncol. 2020 Jun;27(6):2017-2024. doi: 10.1245/s10434-019-08161-6. Epub 2020 Jan 3.
5. Taghizadeh H, Müllauer L, Mader RM, **Schindl M**, Prager GW.  
Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.  
Ther Adv Med Oncol. 2020 Jul 10;12:1758835920938611. doi: 10.1177/1758835920938611.
6. Kieler M, Unseld M, Bianconi D, **Schindl M**, Kornek GV, Scheithauer W, Prager GW.  
Impact of new chemotherapy regimens on the treatment landscape and survival of locally advanced and metastatic pancreatic cancer patients.  
J Clin Med. 2020 Feb 28;9(3):648. doi: 10.3390/jcm9030648.
7. Beer L, Toepker M, Ba-Ssalamah A, Schestak C, Dutschke A, **Schindl M**, Wressnegger A, Ringl H, Apfaltrer P.  
Objective and subjective comparison of virtual monoenergetic vs. polychromatic images in patients with pancreatic ductal adenocarcinoma.

- Eur Radiol. 2019 Jul;29(7):3617-3625. doi: 10.1007/s00330-019-06116-9. Epub 2019 Mar 19.
8. Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, **Schindl M**. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. *J Gastrointest Surg*. 2019 Mar 28. doi: 10.1007/s11605-019-04187.
  9. Gruber ES, Jomrich G, Tamandl D, Gnant M, **Schindl M**, Sahora K. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. *PLoS One*. 2019 May 6;14(5):e0215915. doi: 10.1371/journal.pone.0215915. eCollection 2019.
  10. Stutchfield BM, Bodingbauer MW, Adair A, Wakelin S, **Schindl M**, Forbes SJ, et al. Quantifying changes in innate immune function following liver transplantation for chronic liver disease. *HPB (Oxford)*. 2019 Mar 5.
  11. **Schindl M**, Függer R, Götzinger P, Längle F, Zitt M, Stättner S, et al. Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. *Br J Surg*. John Wiley & Sons, Ltd; 2018 Jun;105(7):811–9.
  12. Chamokova B, Bastati N, Poetter-Lang S, Bican Y, Hodge JC, **Schindl M**, et al. The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases. *The British Journal of Radiology*. The British Institute of Radiology; 2018 Apr;91(1084):20170677.
  13. Bolliger M, Kroehnert JA, Molineus F, Kandioler D, **Schindl M**, Riss P. Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients. *Eur Surg*. 2018;50(6):256–61.
  14. Scheithauer W, Kornek G, Prager G, Stranzl N, Laengle F, **Schindl M**, et al. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. *J Gastrointest Oncol*. 2016 Apr;7(2):234–8.
  15. Muschitz GK, Fochtman A, Keck M, Ihra GC, Mittlböck M, Lang S, **Schindl M**, et al. Non-occlusive mesenteric ischaemia: the prevalent cause of gastrointestinal infarction in patients with severe burn injuries. *Injury*. 2015 Jan;46(1):124–30.
  16. Koperek O, Aumayr K, **Schindl M**, Werba G, Soleiman A, Schoppmann S, et al. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma. *APMIS*. John Wiley & Sons, Ltd (10.1111); 2014 Jun;122(6):476–81.

17. Sahora K, **Schindl M**, Kuehrer I, Eisenhut A, Werba G, Brostjan C, et al. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. *Anticancer Res.* 2014 May;34(5):2377–84.
18. Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, **Schindl M** et al. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. *World J Surg.* Springer US; 2014 Feb;38(2):456–62.
19. Aumayr K, Soleiman A, Sahora K, **Schindl M**, Werba G, Schoppmann SF, et al. HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas. *Appl Immunohistochem Mol Morphol.* 2014;22(2):146–52.
20. Wibmer A, Prusa AM, Nolz R, Gruenberger T, **Schindl M**, Ba-Ssalamah A. Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. *Radiology.* Radiological Society of North America; 2013 Dec;269(3):777–86.
21. Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, Gruenberger T, **Schindl M** et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. *Eur J Surg Oncol.* 2012 Aug;38(8):670–6.
22. Peck-Radosavljevic M, Sieghart W, Kölblinger C, Reiter M, **Schindl M**, Ulbrich G, et al. Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. *Wien Klin Wochenschr.* Springer-Verlag; 2012 Feb;124(3-4):104–10.
23. Sahora K, Kuehrer I, **Schindl M**, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. *World J Surg.* 6 ed. Springer-Verlag; 2011 Jul;35(7):1580–9.
24. Rutter K, Ferlitsch A, Sautner T, Püspök A, Götzinger P, Gangl A, **Schindl M**. Hospitalization, frequency of interventions, and quality of life after endoscopic, surgical, or conservative treatment in patients with chronic pancreatitis. *World J Surg.* Springer-Verlag; 2010 Nov;34(11):2642–7.
25. Schneider R, Gollackner B, **Schindl M**, Tucek G, Auer H. *Echinococcus canadensis* G7 (pig strain): an underestimated cause of cystic echinococcosis in Austria. *Am J Trop Med Hyg.* 2010 May;82(5):871–4.
26. Tamandl D, Herberger B, Gruenberger B, Schoppmann SF, Puhalla H, **Schindl M**, et al. Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases. *Surgery.* 2008 May;143(5):648–57.

27. Schima W, Ba-Ssalamah A, Kurtaran A, **Schindl M**, Gruenberger T. Post-treatment imaging of liver tumours. *Cancer Imaging. BioMed Central*; 2007 Oct 1;7 Spec No A(Special Issue A):S28–36.
28. Tamandl D, Gruenberger B, Herberger B, Schoppmann S, Bodingbauer M, **Schindl M**, et al. Selective resection of colorectal liver metastases. *European Journal of Surgical Oncology*. 2007 Mar;33(2):174–82.
29. **Schindl MJ**, Millar AM, Redhead DN, Fearon KCH, Ross JA, Dejong CHC, et al. The adaptive response of the reticuloendothelial system to major liver resection in humans. *Ann Surg*. 2006 Apr;243(4):507–14.
30. **Schindl MJ**, Redhead DN, Fearon KCH, Garden OJ, Wigmore SJ, Edinburgh Liver Surgery and Transplantation Experimental Research Group (eLISTER). The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. *Gut. BMJ Publishing Group*; 2005 Feb;54(2):289–96.
31. **Schindl M**, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. *Arch Surg. American Medical Association*; 2005 Feb;140(2):183–9.
32. Kaczirek K, **Schindl M**, Weinhäusel A, Scheuba C, Passler C, Prager G, et al. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. *J Clin Endocrinol Metab*. 2004 May;89(5):2397–401.
33. Kaczirek K, Soleiman A, **Schindl M**, Passler C, Scheuba C, Prager G, et al. Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism. *Eur J Clin Invest*. 2003 Jun;33(6):488–92.
34. Loewe C, **Schindl M**, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. *AJR Am J Roentgenol. American Roentgen Ray Society*; 2003 May;180(5):1379–84.
35. Kettenbach J, Müller SL, **Schindl M**. [Interventional therapy of neuroendocrine tumors of the gastrointestinal tract]. *Wien Klin Wochenschr*. 2003;115 Suppl 2:56–64.
36. Prager G, Heinz-Peer G, Passler C, Kaczirek K, **Schindl M**, Scheuba C, et al. Can dynamic gadolinium-enhanced magnetic resonance imaging with chemical shift studies predict the status of adrenal masses? *World J Surg. Springer-Verlag*; 2002 Aug;26(8):958–64.
37. **Schindl M**, Kaczirek K, Passler C, Kaserer K, Prager G, Scheuba C, et al. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? *World J Surg. Springer-Verlag*; 2002 Aug;26(8):976–84.

38. Kaczirek K, Prager G, **Schindl M**, Kaserer K, Gessl A, Vierhapper H, et al. Multiple endocrine neoplasia 1--current recommendations for diagnosis and treatment. *Wien Klin Wochenschr.* 2002 Apr 15;114(7):258–66.
39. Prager G, Heinz-Peer G, Passler C, Kaczirek K, **Schindl M**, Scheuba C, et al. Surgical strategy in adrenal masses. *Eur J Radiol.* 2002 Jan;41(1):70–7.
40. **Schindl M**, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. *Arch Surg.* 2001 Jan;136(1):49–54.
41. Soliman T, Pokorny H, Rockenschaub S, Langer F, Puhalla H, Grünberger T, **Schindl M** et al. First experiences with mesh wrapping for parenchymal liver injuries in orthotopic liver transplantation. *Transplant Proc.* 1999 Feb;31(1-2):538–9.
42. Windberger UB, Auer R, Keplinger F, Längle F, Heinze G, **Schindl M**, et al. The role of intra-abdominal pressure on splanchnic and pulmonary hemodynamic and metabolic changes during carbon dioxide pneumoperitoneum. *Gastrointest Endosc.* 1999 Jan;49(1):84–91.
43. Yeganehfar W, Wamser P, Rockenschaub S, **Schindl M**, Mittlböck M, Eisenhuber E, et al. [Liver transplantation in acute liver failure]. *Wien Klin Wochenschr.* 1998 Sep 4;110(16):570–8.
44. **Schindl M**, Niederle B, Häfner M, Teleky B, Längle F, Kaserer K, et al. Stage-dependent therapy of rectal carcinoid tumors. *World J Surg.* 1998 Jun;22(6):628–33–discussion634.
45. Längle F, Steininger R, Waldmann E, Grünberger T, Benditte H, Mittlböck M, Soliman T, **Schindl M**, et al. Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation. *Transplantation.* 1997 May 15;63(9):1225–33.
46. **Schindl M**. [Congenital abnormalities of the osseous thoracic wall. Results of corrective surgery of funnel chest]. *Wien Klin Wochenschr.* 1995;107(5):175–8.